title: Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?
authors.affiliation: *IBD Center, Division of Gastroenterology, Virginia Tech-Carilion School of Medicine, Roanoke, Virginia; †Nutritional Immunology and Molecular Medicine Laboratory, Virginia Bioinformatics Institute, Virginia Tech, Blacksburg, Virginia; ‡Department of Clinical and Experimental Medical Sciences, University of Udine Medical School, Udine, Italy; and §Department of Medicine, University of Queensland-Brisbane, Brisbane, Australia.
authors.forename: Dario
authors.initials: D
authors.lastname: Sorrentino
authors.forename: Peter
authors.initials: P
authors.lastname: Nash
authors.forename: Monica
authors.initials: M
authors.lastname: Viladomiu
authors.forename: Raquel
authors.initials: R
authors.lastname: Hontecillas
authors.forename: Josep
authors.initials: J
authors.lastname: Bassaganya-Riera
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000276:immunology* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008134:Long-Term Care / Q000379:methods; D012008:Recurrence; D012074:Remission Induction; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D028761:Withholding Treatment
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab